亚洲知识产权资讯网为知识产权业界提供一个一站式网上交易平台,协助业界发掘知识产权贸易商机,并与环球知识产权业界建立联系。无论你是知识产权拥有者正在出售您的知识产权,或是制造商需要购买技术以提高操作效能,又或是知识产权配套服务供应商,你将会从本网站发掘到有用的知识产权贸易资讯。

CorA human medicine

总结
Corallopyronin A is a new antibiotic in filarial and dirofilarial infections with a new mode of action resulting in fewer adverse reaction and unlikelyness of resistances development.
技术优势
Effective control of dirofilarial infections
Kills larvae as well as adult worms
Requires fewer treatment cycles in logistically difficult regions
Treatment of children is probable
Oral administration is possible
Alternative mode of action avoids selection for rifampicin cross-resistant M. tuberculosis
技术应用
The current treatment approach targets the worm itself. The drugs, e.g. diethylcarbamazine and ivermectin, mainly kill larvae.
详细技术说明
Corallopyronin A (CorA) has efficacy against the intracellular Wolbachia of filarial nematodes. Experiments in mice show that all worms were depleted of more than 98% of their Wolbachia, resulting in blocked larval development and phenotypically altered worms. The results indicate the potential of CorA to effectively eliminate filarial disease by killing larvae as well as adult worms with one (maximum of two) treatment regimens.
合作类型
Licensing
申请日期
04/05/2012 00:00:00
申请号码
EP20120721456 20120504
分类
- international:
A61K31/366; A61P31/04; A61P33/00
- cooperative:
A61K31/366; C07D309/38; Y02A50/421; Y02A50/422
其他
Patent application
ID号码
2838
国家/地区
德国

欲了解更多信息,请点击 这里
移动设备